Does doxycycline (Doxy) cover Methicillin-resistant Staphylococcus aureus (MRSA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2025 • View editorial policy

From the Guidelines

Doxycycline can be effective against some strains of Methicillin-resistant Staphylococcus aureus (MRSA), but its effectiveness varies depending on local resistance patterns, the site and severity of infection, and individual patient factors. For mild to moderate community-acquired MRSA skin and soft tissue infections, doxycycline may be prescribed at a dose of 100mg twice daily for 7-14 days 1. However, for more severe or invasive MRSA infections, vancomycin, linezolid, or daptomycin are typically preferred. Doxycycline works by inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, which prevents bacterial growth and replication. Some key points to consider when using doxycycline for MRSA infections include:

  • Local resistance patterns: The effectiveness of doxycycline against MRSA can vary depending on local resistance patterns, so it's essential to consider the prevalence of resistant strains in the area 2.
  • Site and severity of infection: Doxycycline may be more effective for mild to moderate infections, while more severe infections may require alternative treatments 3.
  • Individual patient factors: Patient factors, such as age, comorbidities, and pregnancy status, can influence the effectiveness and safety of doxycycline 4. Before using doxycycline for suspected MRSA infections, culture and susceptibility testing should ideally be performed to confirm that the specific MRSA strain is susceptible to this antibiotic 5. Additionally, doxycycline should be used cautiously in pregnant women and children under 8 years due to potential effects on bone development and tooth discoloration.

From the Research

Doxy Covers MRSA

  • Doxycycline is one of the oral antibiotics used to treat community-acquired MRSA (CA-MRSA) skin and soft-tissue infections 6.
  • However, doxycycline often fails to eradicate the infection, and its effectiveness is not always predictable based on in vitro susceptibilities 6.
  • In a study comparing the activities of various antimicrobial compounds against CA-MRSA, doxycycline demonstrated significant kill against a clindamycin noninducible strain, but only bacteriostatic activity against clindamycin resistance-inducible isolates 7.
  • Other treatment options for MRSA infections include vancomycin, linezolid, daptomycin, and ceftaroline, which have shown effectiveness in various studies 8, 9.
  • The choice of antibiotic for MRSA treatment depends on various factors, including the severity of the infection, the patient's medical history, and the susceptibility of the MRSA isolate to different antibiotics 8, 9.

Treatment Options for MRSA

  • Vancomycin is a commonly used antibiotic for MRSA treatment, but its effectiveness can be limited by the development of resistance 8, 9.
  • Linezolid and daptomycin have shown effectiveness in treating MRSA infections, including those caused by strains with reduced susceptibility to vancomycin 8, 9.
  • Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA, and has been shown to be non-inferior to vancomycin in treating skin and soft-tissue infections 8.
  • Doxycycline and other oral antibiotics, such as clindamycin and trimethoprim-sulfamethoxazole, may be used to treat uncomplicated MRSA skin and soft-tissue infections, but their effectiveness can be limited by the development of resistance 6, 10, 7.

References

Research

Treatment of infections due to resistant Staphylococcus aureus.

Methods in molecular biology (Clifton, N.J.), 2014

Research

Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond.

Seminars in respiratory and critical care medicine, 2015

Research

Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections.

Journal of the American Board of Family Medicine : JABFM, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.